Skip to main content


  • Poster presentation
  • Open Access
  • Association of microRNA-221/222 and -323-3p with rheumatoid arthritis via predictions using the human TNF transgenic mouse model

    • 1,
    • 2,
    • 1, 3,
    • 3,
    • 4,
    • 5,
    • 4,
    • 5, 6,
    • 2 and
    • 1
    Arthritis Research & Therapy201214 (Suppl 1) :P59

    • Published:


    • Rheumatoid Arthritis
    • Rheumatoid Arthritis Patient
    • Deep Sequencing
    • Synovial Fibroblast
    • Predict Gene Target


    MicroRNAs (miRs), a class of small non-coding RNA molecules, act as posttranscriptional regulators and are involved in a plethora of cellular functions. miRs have attracted a great deal of attention as potential therapeutic targets, as the sequence-specific mode in which they act, allows the simultaneous targeting of multiple target genes, often members of the same biological pathway(s) [1]. Previous studies have demonstrated that miRs are dysregulated and functionally involved in rheumatoid arthritis (RA) [29]. In this study we sought to identify novel miR associations in synovial fibroblasts (SFs), a key pathogenic cell type in RA [10, 11], by performing miR expression profiling on cells isolated from the human TNF transgenic mouse model (TghuTNF, Tg197) [12] and patients biopsies.

    Materials and methods

    miR expression in SFs from TghuTNF and WT control mice were determined by deep sequencing and the arthritic profile was established by pairwise comparisons. qRT-PCR analysis was utilised for profile validation, miR and gene quantitation in patient SFs. Dysregulated miR target genes and pathways were predicted via bioinformatic algorithms.


    Deep sequencing demonstrated that TghuTNF-SFs exhibit a distinct pathogenic profile with 22 significantly upregulated and 30 significantly downregulated miRs (fold change>1.5, p-value<0.05). qRT-PCR validation assays confirmed the dysregulation of miR-223, miR-146a and miR-155 previously associated with human RA pathology, as well as that of miR-221/222 and miR-323-3p. Notably, the latter were also found significantly upregulated in patient RASFs, suggesting their association with human RA pathology. Bioinformatic analysis suggested Wnt/Cadherin signaling as the most significant pathway targets of miR-221/222 and miR-323-3p and CSNK1A1 and BTRC, the negative regulators of β-catenin, amongst predicted gene targets. qRT-PCR assays confirmed the downregulation of these genes in RASFs, validating our hypothesis that the newly identified miRs may function to modulate Wnt/Cadherin signaling.


    In this study, by performing comparative analyses between an established mouse model of arthritis and RA patient biopsies, we identified novel dysregulated miRs in RASFs potentially involved in pathways important for the pathogenic phenotype of these cells and highlighting the value of such cross-species comparative approaches [13].



    This project was funded by the Masterswitch Project (HEALTH-F2-2008-223404), EURO-RA RTN (HPRN-CT-2002-00255) and IMI BtCure (grant agreement No 115142) grants to GK and SG. JR was supported by the Wellcome Trust grant 075491/Z/04. In SG also received funding from IAR-EPALINGES.

    Authors’ Affiliations

    Institute of Immunology, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece
    Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology, Zurich, Switzerland
    Biomedcode Hellas SA, Vari, Greece
    Institute of Molecular Oncology, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Institute of Molecular Biology & Genetics, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece


    1. Montgomery RL, van Rooij E: microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease. Curr Drug Targets. 2010, 11 (8): 936-942. 10.2174/138945010791591368.View ArticlePubMedGoogle Scholar
    2. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T: Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010, 12 (3): R86-10.1186/ar3013.PubMed CentralView ArticlePubMedGoogle Scholar
    3. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10 (4): R101-PubMed CentralView ArticlePubMedGoogle Scholar
    4. Kawano S, Nakamachi Y: miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis. 2011, 70: I88-I91. 10.1136/ard.2010.138669.View ArticlePubMedGoogle Scholar
    5. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, et al: Altered expression of MicroRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 2011, 63 (2): 373-381. 10.1002/art.30115.PubMed CentralView ArticlePubMedGoogle Scholar
    6. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58 (4): 1001-1009. 10.1002/art.23386.View ArticlePubMedGoogle Scholar
    7. Bluml S, Bonelli M, Niederreiter B, Puchner A, Mayr G, Hayer S, Koenders MI, van den Berg WB, Smolen J, Redlich K: Essential role for micro-RNA 155 in the pathogenesis of autoimmune arthritis. Arthritis Rheum. 2011, 63 (5): 1281-8. 10.1002/art.30281.View ArticlePubMedGoogle Scholar
    8. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, et al: MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011, 108 (27): 11193-8. 10.1073/pnas.1019536108.PubMed CentralView ArticlePubMedGoogle Scholar
    9. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M: The inhibitory effect of microRNA-146 expression on bone destruction in arthritis. Arthritis Rheum. 2011, 63 (6): 1582-90. 10.1002/art.30321.View ArticlePubMedGoogle Scholar
    10. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G: Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008, 205 (2): 331-337. 10.1084/jem.20070906.PubMed CentralView ArticlePubMedGoogle Scholar
    11. Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnaker E-M, Tarner IH, Robbins PD, et al: Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009, 15 (12): 1414-1420. 10.1038/nm.2050.PubMed CentralView ArticlePubMedGoogle Scholar
    12. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10 (13): 4025-4031.PubMed CentralPubMedGoogle Scholar
    13. Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, Baumans V, Desaintes C, Di Santo J, Distler J, Garside P, et al: Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis. 2011, 70 (8): 1357-1362. 10.1136/ard.2010.148551.View ArticlePubMedGoogle Scholar


    © Pandis et al.; licensee BioMed Central Ltd. 2012

    This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.